Table 1. Characteristics of patients included in this study.
| Characteristic | Result |
|---|---|
| Age (years) | P=0.001 |
| Non-PCA | 69.0±7.2 |
| PCA | 66.2±7.2 |
| PSA (ng/mL) | P<0.001 |
| Non-PCA | 12.21 (7.40, 23.35) |
| PCA | 9.52 (5.91, 14.36) |
| Pathology | |
| Non-PCA | 131 (42.4) |
| TZ-BPH | 96 |
| PZ-inflammation | 35 |
| PCA | 178 (57.6) |
| PCA-TZ | 61 |
| PCA-PZ | 117 |
| Final GS | |
| Low-risk PCA | 62 (34.8) |
| 3+3 | 7 |
| 3+4 | 55 |
| Intermediate-high PCA | 116 (65.2) |
| 4+3 | 67 |
| 4+4 | 32 |
| 4+5 | 17 |
| GS ≤3+4 by TTPB | |
| Upgraded | 18 (26.5) |
| 3+3 → 4+3 | 1 |
| 3+4 → 4+3 | 16 |
| 3+4 → 4+5 | 1 |
| Non-upgraded | 50 (73.5) |
| 3+3 → 3+3 | 6 |
| 3+3 → 3+4 | 15 |
| 3+4 → 3+4 | 29 |
Data following a normal distribution are expressed as the mean ± standard deviation. Otherwise, data are expressed as the median (first quartile, third quartile) or n or n (%). PCA, prostate cancer; PSA, prostate-specific antigen; TZ, transformation zone; BPH, benign prostatic hyperplasia; PZ, peripheral zone; GS, Gleason Score; TTPB, transperineal prostate biopsy.